Introduction: Gall Bladder Carcinoma (GBC) is a diagnostic
and a therapeutic challenge. Although it is increasing, chronic
cholecystitis remains the most worldwide gall bladder lesions,
harboring many epithelial changes that may end in carcinoma.
Aim: To investigate the expression of HER2/neu (Human
Epidermal Growth Factor Receptor 2), Ki-67 and MUC1 (Mucin
1) in malignant and non-malignant gall bladder lesions, and to
evaluate its relation with clinicopathologic parameters of GBC.
Materials and Methods: This retrospective study included
40 cases of GBC, eight cases of gall bladder dysplasia,
10 cases of gall bladder metaplastic changes and 25 cases
of chronic cholecystitis as a control group. The blocks
were collected from the Department of Pathology of Benha
University Hospital, from January 2012 to December 2019.
Immunohistochemical staining results of HER2/neu, Ki-67 and
MUC1 were analysed and correlated by Statistical Package
for the Social Sciences (SPSS) version 16 and Chi-square test
or Fisher’s-exact tests.
Results: Positive HER2/neu expression (+2, +3) was detected
in 47.5% (19/40) of malignant cases and 12.5% (1/8) of
Keywords: Cell surface associated, Gall bladder carcinoma, Human epidermal growth factor receptor, Ki labeling index
Tyrosine Kinase (TK) has been recently implicated in pathogenesis
of various neoplasms. Several oncogenes, which encode for growth
factor receptors, have TK activity. The EGFR family includes the
Epidermal Growth Factor Receptor (EGFR, HER-1) and c-erbB-2
(HER-2) are with TK activity [5]. HER-2 is a normal cellular gene,
also called c-erbB2, located on chromosome 17q12q21.28. It
encodes a TK that is strongly related to receptor for EGFR [6]. The
dyspastic group, in the same time it was completely absent
in the metaplastic and cholecystitis cases (p |
